# OnCo record paper-zanubrutinib-cll-lancet-oncol-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-zanubrutinib-cll-lancet-oncol-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-zanubrutinib-cll-lancet-oncol-2022" ;
  schema:name "Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial"@en ;
  schema:description "Phase 2 or 3 results paper on Zanubrutinib in Chronic lymphocytic leukaemia, in The Lancet Oncology (2022), one of the most cited Europe PMC records with Zanubrutinib in its title."@en ;
  schema:url <https://onco.cc/key-papers/paper-zanubrutinib-cll-lancet-oncol-2022/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s1470-2045(22)00293-5>, <https://pubmed.ncbi.nlm.nih.gov/35810754/>, <https://europepmc.org/article/MED/35810754>, <https://clinicaltrials.gov/study/NCT03336333> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s1470-2045(22)00293-5> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Tam CS, Brown JR, Kahl BS, et al." ;
  onco:trials <https://onco.cc/trials/sequoia/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .